Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The impact of G9a-inhibitors in T-cell and Treg differentiation

ABSTRACT: The impact of G9a-inhibitors in T-cell and Treg differentiation

PROVIDER: PRJNA807687 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR17901632_1.fastq.gz	Fastqsanger.gz
	SRR17901632_2.fastq.gz	Fastqsanger.gz
	SRR17901633_1.fastq.gz	Fastqsanger.gz
	SRR17901633_2.fastq.gz	Fastqsanger.gz
	SRR17901634_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 32

Similar Datasets

The impact of G9a-inhibitors in T-cell and Treg differentiation [ATAC-seq]

Project description:The impact of G9a-inhibitors in T-cell and Treg differentiation [ATAC-seq]

| PRJNA807689 | ENA

The impact of G9a-inhibitors in T-cell and Treg differentiation [RNA-Seq]

Project description:The impact of G9a-inhibitors in T-cell and Treg differentiation [RNA-Seq]

| PRJNA803925 | ENA

The impact of G9a-inhibitors in T-cell and Treg differentiation [RNA-Seq]

Project description:As methyltransferase G9a has been implicated in immune cell differentiation we have assessed the role of G9a enzymatic inhibitors (UNC0642) in the differentiation of human naïve T-cells under different stimulation conditions.

2022-12-31 | GSE196226 | GEO

The impact of G9a-inhibitors in T-cell and Treg differentiation [ATAC-seq]

2022-12-31 | GSE196903 | GEO

The impact of G9a-inhibitors in T-cell and Treg differentiation

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-12-31 | GSE196904 | GEO

Change in transcriptome upon G9a knockdown in RD ERMS (Embryonal Rhabdomyosarcoma) cells

Project description:The Wnt signaling pathway is down-regulated in embryonal rhabdomyosarcoma (ERMS) and contributes to the block of myogenic differentiation. Epigenetic mechanisms leading to its suppression are unknown and could pave the way towards novel therapeutic modalities. In this study, we demonstrate that the lysine methyltransferase G9a suppresses the canonical Wnt signalling pathway by activating expression of the Wnt antagonist DKK1. Inhibition of G9a expression or activity reduced DKK1 expression and elevated canonical Wnt signalling resulting in myogenic differentiation in vitro and in vivo. Mechanistically, G9a impacted Sp1 and p300 enrichment at the DKK1 promoter in a methylation-dependent manner. The reduced tumor growth upon G9a deficiency was reversed by recombinant DKK1 or LGK974, which also inhibits Wnt signaling. Consistently, among thirteen drugs targeting chromatin modifiers, G9a inhibitors were highly effective in reducing ERMS cell viability. Together, our study demonstrates that ERMS cells are vulnerable to G9a inhibitors and suggest that targeting the G9a-DKK1--catenin node holds promise for differentiation therapy.

2020-12-16 | GSE142975 | GEO

P220-1: CDK8 in Treg differentiation

Project description:P220-1: CDK8 in Treg differentiation

| PRJNA595345 | ENA

P220-1: CDK8 in Treg differentiation

Project description:Immune health requires innate and adaptive immune cells to engage precisely balanced pro- and anti-inflammatory forces. A holistic understanding of how individual small molecules affect this balance is essential to anticipate immune-related side effects, select mitigating immunomodulatory therapies and highlight novel utility as immunomodulators. We previously showed that the high-specificity, low-toxicity cyclin dependent kinase 8 (CDK8) inhibitor DCA promotes tolerogenic effects in innate immune cells. Here, we demonstrate that DCA exerts a novel profile of tolerogenic activity on CD4+ T cells, promoting Treg and Th2 while inhibiting Th1 and Th17 differentiation. DCA enhances human Treg differentiation and our models demonstrate clear tolerogenic function of DCA-driven Tregs in the absence of confounding contribution from DCA-innate immune interactions. DCA engages unique mechanisms, including specifically enhancing early Foxp3 expression via regulating c-Jun phosphorylation, to promote Treg differentiation. CDK8 inhibitors are currently being developed to treat cancer; our findings suggest that the potential blunting of host-versus-tumor effects may warrant ancillary pro-inflammatory agents. Importantly, these results highlight novel utility of DCA as an immunomodulator, not only in vivo, but also in ex vivo cellular therapy.

2021-07-28 | GSE141933 | GEO

Unexpected distinct roles of the related histone H3 lysine 9 methyltransferases G9a and G9a-Like Protein in myoblasts

Project description:Lysine methyltransferases G9a and GLP (G9a- Like Protein) form functional heterodimeric complexes that establish mono- and dimethylation on histone H3 lysine 9 (H3K9me1, H3K9me2) in euchromatin. Here we describe unexpected opposite individual roles for G9a and GLP during skeletal muscle terminal differentiation. Indeed, gain- or loss-of-function assays in myoblasts showed that in consistency with previous reports that G9a inhibits terminal differentiation. But GLP plays a more complicated role in muscle differentiation since both knockdown and overexpression inhibits terminal differentiation. Unexpectedly, in contrast to G9a, we show that GLP overexpression promotes abnormal expression of muscle differentiationspecific genes in proliferating myoblasts. Transcriptomic analysis indicates that G9a and GLP regulate different sets of genes. GLP, but not G9a, inhibits at the transcriptional level proteasome subunit-encoding genes resulting in an inhibition of the proteasome activities. Subsequently, GLP, but not G9a, overexpression stabilizes MyoD that is likely to be responsible for muscle markers expression in proliferating myoblasts.

2016-02-01 | GSE72626 | GEO

Impact of Tcf1/Lef1 deficiency on Treg cells

Project description:Impact of Tcf1/Lef1 deficiency on Treg cells

| PRJNA490202 | ENA